Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 34128042)

  • 21. Cost of shifting from healthcare to long-term care in later life across major diseases: analysis of end-of-life care during the last 24 months of life.
    Terada T; Nakamura K; Seino K; Kizuki M; Inase N
    J Rural Med; 2018 May; 13(1):40-47. PubMed ID: 29875896
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug Monographs: Trabectedin and Trifluridine-Tipiracil.
    Solimando DA; Waddell JA
    Hosp Pharm; 2016 Feb; 51(2):120-128. PubMed ID: 38746764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trifluridine/Tipiracil: Old Drug, New Tricks.
    Jeffers KD
    J Adv Pract Oncol; 2016; 7(4):449-453. PubMed ID: 29226002
    [No Abstract]   [Full Text] [Related]  

  • 24. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
    Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
    Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
    Ueno M; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ikeda M; Ozaka M; Okano N; Sugimori K; Todaka A; Shimizu S; Mizuno N; Yamamoto T; Sano K; Tobimatsu K; Katanuma A; Miyamoto A; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Miyakawa H; Yamashita T; Yasuda I; Takahashi H; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
    Sci Rep; 2021 Jun; 11(1):12885. PubMed ID: 34145336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
    Sugawara S; Lee JS; Kang JH; Kim HR; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Namba Y; Sumiyoshi N; Nakagawa K
    Ann Oncol; 2021 Sep; 32(9):1137-1147. PubMed ID: 34139272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
    Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
    Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
    Okuyama A; Boku N; Higashi T
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1482. PubMed ID: 34176233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
    Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
    ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
    Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
    Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.
    Lang Y; Lin Y; Li D; Liu J; Liu X
    Cancer Med; 2023 Sep; 12(18):18447-18459. PubMed ID: 37706223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients.
    Ferrario L; Asperti F; Aprile G; Giuliani J
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment.
    Lu Y; Dai Z; Chang F; Wang L; He J; Shi P; Zhang H; Lu Y
    Pharmacoeconomics; 2023 Mar; 41(3):295-306. PubMed ID: 36658308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
    Shu Y; Ding Y; Zhang Q
    Front Oncol; 2022; 12():851522. PubMed ID: 35515123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
    Jiang Y; Li Y; Wang LXW
    Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
    Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
    Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.